Management of Prostate Cancer: A Case-Based Approach with Emphasis on Integrating New Molecular Diagnostics into Clinical Practice Webcast 078IC (2018)

This course will provide a practical, evidence-based approach for the management of everyday problems in the management of prostate cancer, using a case-based approach with examples from real practice. Cases will illustrate contemporary management of early and late stage disease with emphasis on how new molecular diagnostic and prognostic tests (PCA3, MDx Confirm, Mitomics, Prolaris, Oncotype Dx Prostate, Decipher, and others) can be used for improved clinical decision making in screening, decisions on initial biopsy and rebiopsy, choosing and following men for active surveillance, and managing PSA failures. In addition, best practice use of newer agents for management of castrate-resistant disease will be reviewed, including the potential for use of targeted therapies based on genomic analysis of advanced tumors. The course will be of interest to individuals at all levels of clinical experience.


This educational series is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Genomic Health
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Medivation, Inc. a Pfizer company
  • Sanofi Genzyme.

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  • Design appropriate screening strategies based on individual demographics, risk factors, and PSA history and to incorporate new biomarkers into routine clinical practice
  • Distinguish and understand the use of new molecular and genomic based tests for decisions on initial and re-biopsy, and choosing and following men on surveillance
  • Appraise the role of surveillance, focal therapy, surgery, and various forms of radiation therapy in patients with low and intermediate risk disease, including adjuvant and salvage radiation
  • Review the role of surgery in the multimodality treatment of men presenting with oligometastatic disease
  • Describe new therapeutic agents for the management of castrate resistant disease and outline a coherent strategy for their use
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 

Course Director:

Eric Klein, MD: GenomeDx Biosciences: Consultant or Advisor, Scientific Study or Trial; Genomimc Health: Consultant or Advisor; Berg: Consultant or Advisor; Cellanyx: Consultant or Advisor


Course Faculty: 

Andrew Stephenson, MD: Genomic Health: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor

Method of Participation
To claim CME credit/hours of participation, the learner must view the webcast, complete the post-test passing with 80% accuracy and submit the activity evaluation.
Estimated time to complete this activity: 2.00 hour
Release Date: June, 2018
Expiration Date: June, 2019

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1.00 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgements: Support provided by an independent education grant from AbbVie, Astellas, Genomic Health, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Medivation, Inc. a Pfizer company and Sanofi Genzyme.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.